Last reviewed · How we verify
KRN951
At a glance
| Generic name | KRN951 |
|---|---|
| Sponsor | Kyowa Kirin Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers (PHASE1, PHASE2)
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma (PHASE2)
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (PHASE3)
- Tivozanib + Enzalutamide in Adv Prostate Cancer (PHASE2)
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (PHASE1, PHASE2)
- Real World Evidence of Tivozanib as First-line Treatment for Metastatic Clear Cell Renal Cell Carcinoma
- RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KRN951 CI brief — competitive landscape report
- KRN951 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI